Vol 6, Supplement 7 (October 2017): Translational Cancer Research

Editorial

The importance of RET-directed therapy in patients with RET- rearranged non-small cell lung cancer
Kiyotaka Yoh
Mitochondrial calcium: a crucial hub for cancer cell metabolism?
Wolfgang F. Graier, Roland Malli
Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy
Vincent C. O. Njar
Immunotherapy in endometrial cancer: who are the most appropriate patients?
Katherine C. Kurnit, Amir A. Jazaeri
The future of prostate cancer precision medicine: anti-ERG therapies
Mani Roshan- Moniri, Michael Hsing, Paul S. Rennie, Artem Cherkasov, Michael E. Cox
BCL9L and caspase-2—new guardians against aneuploidy
Narendra Kumar Chunduri, Zuzana Storchova
Mighty RapaLink-1 vanquishes undruggable mutant mTOR in glioblastoma
Meena Jhanwar-Uniyal
Mixing, matching and modifying the prostate cancer microenvironment
Susan F. Slovin
Auto-antibodies against P53—a useful complementary biomarker for ovarian cancer screening?
Rudolf Kaaks, Renée T. Fortner
“Wonder drugs” in central nervous system lymphoma
Agnieszka Korfel
Fucosyltransferase 8 as a driver of melanoma metastasis: a new target for melanoma therapy?
Chi-Huey Wong, Tsui-Ling Hsu
Morphine, when used for treating patients with acute pancreatitis, could be more risky than previously suspected
Juan Iovanna, Maria Cecilia Mallmann
About rearranged during transfection in non-small cell lung cancer
Cesare Gridelli, Tania Losanno
Brigatinib, a new treatment option in ALK-rearranged advanced non-small cell lung carcinoma
Etienne Giroux Leprieur, Marie Wislez
Targeted therapies of HER2-positive gastric adenocarcinoma
Arik Bernard Schulze, Andrea Kerkhoff, Georg Lenz, Torsten Kessler
Liquid biopsies: envisioning a future when tissue is avoidable in lung cancer treatment decision-making
Noelia Vilariño, Roxana Reyes, Cristina Teixidó, Noemi Reguart
Overcoming resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer
Shoko Noda- Narita, Shintaro Kanda
Notch signalling: the true driver of small cell lung cancer?
Laure Marignol
Targeting glioblastoma stem-cells: a recurrent challenge in neurooncology
Giulia Berzero, Alberto Picca, Marc Sanson
Stereotactic conformal radiation therapy in the treatment of benign and low-grade brain tumors
James D. Byrne, Trevor J. Royce, Jay S. Loeffler
Targeting miR-155 in FLT3-ITD mutated AML: ready for prime time?
Edith Schneider, Arefeh Rouhi, Florian Kuchenbauer
Editorial on the use of immunotherapy in renal-cell carcinoma—promising results in combination therapy with ipilimumab and nivolumab
Christian Menzer, Carsten Gruellich, Jessica C. Hassel
Racial disparities in management of hepatocellular carcinoma
Andrea Mancuso
Finding a place for ceritinib in the landscape of ALK-positive nonsmall cell lung cancer
Elaine Shum, Leena Gandhi
Lipid transactions in cancer—the fat addiction and glycerol-3-phosphate acyltransferase action
Prashanth Panta, Bramanandam Manavathi
Nivolumab for chemorefractory oesophageal squamous cell carcinoma
Maxime Chénard-Poirier, Elizabeth C. Smyth
Advanced esophagogastric cancers: the making or breaking of a backbone
Asha Dhanarajan, Shelly Lo
Microphthalmia-associated transcription factors activate mTORC1 through RagD GTPase gene expression
Edith Jones, Ken Inoki
ONC201: a new treatment option being tested clinically for recurrent glioblastoma
Marie D. Ralff, Amriti R. Lulla, Jessica Wagner, Wafik S. El-Deiry
When better still might not be good enough
Waldemar Debinski
Optimal local therapy for early-stage small cell lung cancer: surgery needs a seat at the table
Kathryn E. Engelhardt, David D. Odell, Malcolm M. DeCamp
IDH mutational status and the immune system in gliomas: a tale of two tumors?
Bryan D. Choi, William T. Curry
Cancer relevance of signal recognition particle RNA and other non-coding RNAs in extracellular vesicles
Germana Rappa, Alice Conigliaro, Mark F. Santos, Riccardo Alessandro, Aurelio Lorico
Monitoring response to therapy by testing circulating tumor DNA in urine
Nicola Normanno
Switching gear and looking from a different angle in the treatment of HER2-positive disease
Kazuhiro Araki, Yasuo Miyoshi
Outcomes in BRCA mutation carriers: evaluation of current data for optimal clinical care
Ojas H. Vyas, Virginia G. Kaklamani
Identifying drivers of metastasis; towards a systematic approach
Michael R. Eccles, Aniruddha Chatterjee, Euan J. Rodger
Targeting sphingosine kinase 1 localization as novel target for ovarian cancer therapy
Caterina Bernacchioni, Paola Turano, Chiara Donati
Is there a role for adjuvant pertuzumab in HER2-positive breast cancer?
Marco Mazzotta, Maddalena Barba, Laura Pizzuti, Patrizia Vici
Combining loco-regional treatments in early hepatocellular carcinoma: new achievements overcoming old limitations
Nelci Antunes de Moura, Fernando Gomes Romeiro
The optimal threshold for α-fetoprotein and vitamin K absence or antagonist-II is still an open issue
Shuixiang He, Junbi Hu, Yan Zhao